Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Diseases × Aromatase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 55 Polycystic Ovary Syndrome 3 Neoplasms, Hormone-Dependent 3 Neoplasm Metastasis 2 Carcinoma, Lobular 2 Carcinoma, Intraductal, Noninfiltrating 2 Carcinoma, Ductal, Breast 2 Breast Cancer Female 2 Advanced Breast Cancer 2 Sexuality 1 Osteoporosis 1 Luminal B/HER2-negative Breast Cancer 1 Leiomyoma 1 Infertility 1 Hormone Receptor Positive Breast Carcinoma 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Fractures, Bone 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Endometrial Neoplasms 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Bone Diseases, Metabolic 1 Arthralgia 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Docetaxel 6 palbociclib 5 exemestane 5 Trastuzumab 5 Letrozole 5 Anastrozole 5 entinostat 4 Fulvestrant 4 Cyclophosphamide 4 ribociclib 3 pyrotinib 3 Doxorubicin 3 abemaciclib 2 Sodium Chloride 2 Paclitaxel 2 Lapatinib 2 Gonadotropin-Releasing Hormone 2 Exercise 2 Everolimus 2 Epirubicin 2 Capecitabine 2 Botulinum Toxins, Type A 2 AZD9833 2 sacubitril and valsartan sodium hydrate drug combination 1 pertuzumab 1 pembrolizumab 1 pegfilgrastim 1 ipatasertib 1 gadoterate meglumine 1 figitumumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03910712 2019-04-10

Pyrotinib

Peking Union Medical College Hospital

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡